CMO · Cardiff Oncology, Inc. (CRDF)

Fairooz Kabbinavar

A named executive officer of Cardiff Oncology in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,272,897

Salary $494,400Stock awards $0

FY2023: $1,257,453

2nd of 3 named executive officers at Cardiff Oncology by FY2024 total.

3 named officers on file for Cardiff Oncology, FY2024

Fairooz Kabbinavar’s pay file — $29

  • 2 fiscal years of pay, line by line
  • CRDF’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cardiff Oncology’s whole pay program stands against its peers

  • Cardiff Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CRDF→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A).

Free

Get Fairooz Kabbinavar’s full pay file as a PDF — free

More than this page: up to 10 years of Fairooz’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Fairooz Kabbinavar compensation by year

Cardiff Oncology Summary Compensation Table · all 2 fiscal years held
In US dollars, as Cardiff Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$443,865$494,400
Bonus$0$0
Stock awards$0$0
Option awards$601,468$591,614
Non-equity incentive$212,120$186,883
Pension and deferred compensation$0$0
All other$0$0
Total$1,257,453$1,272,897

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cardiff Oncology, Inc. DEF 14A filed April 29, 2025, accession 0000950170-25-060074, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cardiff Oncology, Inc. filed document, accession 0000950170-25-060074. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

$1.3M
$1.3M
FY23
FY24
SalaryNon-equity incentiveOption awards

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option205,008—$3.51
Option221,354—$1.75

Per the Outstanding Equity Awards at Fiscal Year-End table in Cardiff Oncology, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Cardiff Oncology’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Mark ErlanderChief Executive Officer$2,401,376
Fairooz Kabbinavar · this pageCMO$1,272,897
James LevineChief Financial Officer$1,266,364

The full Cardiff Oncology compensation record

free company brief

This page is one person within Cardiff Oncology's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cardiff Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Fairooz Kabbinavar's compensation dossier · One-time report. No refunds.